Read by QxMD icon Read

treatment hemoglobin prostate cancer

Rana R McKay, Susanna Jacobus, Matthew Fiorillo, Elisa M Ledet, Patrick M Cotogna, Allie E Steinberger, Heather A Jacene, Oliver Sartor, Mary-Ellen Taplin
BACKGROUND: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. PATIENTS AND METHODS: We conducted retrospective analyses of patients who received radium-223 (n = 135)...
August 20, 2016: Clinical Genitourinary Cancer
Nicholas J Vogelzang, Robert E Coleman, Jeff M Michalski, Sten Nilsson, Joe M O'Sullivan, Christopher Parker, Anders Widmark, Marcus Thuresson, Lei Xu, Joseph Germino, Oliver Sartor
BACKGROUND: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk factors will improve clinical decision making. We describe hematologic safety of radium-223 in ALSYMPCA and post hoc analyses identifying patients at increased risk for hematologic toxicity. PATIENTS AND METHODS: Hematologic parameters and adverse events were analyzed...
August 8, 2016: Clinical Genitourinary Cancer
Kenta Miki, Hiroshi Sasaki, Masahito Kido, Hiroyuki Takahashi, Manabu Aoki, Shin Egawa
BACKGROUND: Neoadjuvant androgen deprivation therapy (ADT) has been suggested to confer several clinical benefits in patients with prostate cancer (PCa) undergoing transperineal prostate brachytherapy (TPPB). Unlike gonadotropin-releasing hormone (GnRH) receptor agonists, a GnRH antagonist such as degarelix can achieve castrate levels of testosterone without testosterone flare. However, normalization of serum testosterone levels following completion of neoadjuvant ADT in either form of treatment has never been compared in clinical trials...
2016: BMC Cancer
S Manteniotis, S Wojcik, P Brauhoff, M Möllmann, L Petersen, J R Göthert, W Schmiegel, U Dührsen, G Gisselmann, H Hatt
The olfactory receptor (OR) family was found to be expressed mainly in the nasal epithelium. In the last two decades members of the OR family were detected to be functional expressed in different parts of the human body such as in liver, prostate or intestine cancer cells. Here, we detected the expression of several ORs in the human chronic myelogenous leukemia (CML) cell line K562 and in white blood cells of clinically diagnosed acute myeloid leukemia (AML) patients by RT-PCR and next-generation sequencing...
2016: Cell Death Discovery
Theodoros Karantanos, Styliani Karanika, Gretchen Gignac
Metabolic abnormalities including hyperglycemia and hyperlipidemia have been associated with worse prognosis of prostate cancer (PCa), but there are limited data regarding their impact on the prognosis of castrate-resistant prostate cancer (CRPC) and the response of novel antiandrogens, namely abiraterone acetate (AA) and enzalutamide. Retrospective analysis of 61 patients with CRPC on AA or enzalutamide, treated at the Boston Medical Center, was performed. We evaluated hemoglobin A1c (HbA1c), HDL, LDL, Triglycerides and BMI within 2months before the initiation of treatment with AA or enzalutamide and progression-free survival (PFS) under this treatment...
September 2016: Endocrine-related Cancer
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
August 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Sompol Permpongkosol, Kalayanee Khupulsup, Supatra Leelaphiwat, Sarawan Pavavattananusorn, Supranee Thongpradit, Thanom Petchthong
INTRODUCTION: The long-term effects of long-acting testosterone undecanoate (TU) and androgen receptor CAG repeat lengths in Thai men with late-onset hypogonadism (LOH) have not been reported. AIM: To analyze the 8-year follow-up effects of intramuscular TU therapy on metabolic parameters, urinary symptoms, bone mineral density, and sexual function and investigate CAG repeat lengths in men with LOH. METHODS: We reviewed the medical records of 428 men with LOH who had been treated with TU and 5 patients were diagnosed with prostate cancer during TU therapy...
August 2016: Journal of Sexual Medicine
Ho Seong Jang, Kyo Chul Koo, Kang Su Cho, Byung Ha Chung
PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we aimed to assess the impact of the combined use of androgen deprivation therapy (ADT) with DTX for mCRPC. MATERIALS AND METHODS: We performed a single-institutional retrospective analysis of patients with mCRPC who received either DTX alone (DTX group, n=21) or concurrent DTX and ADT (DTX+ADT group, n=26) between August 2006 and February 2014...
September 2016: Yonsei Medical Journal
David Lorente, Aurelius Omlin, Zafeiris Zafeiriou, Daniel Nava-Rodrigues, Raquel Pérez-López, Carmel Pezaro, Niven Mehra, Elizabeth Sheridan, Ines Figueiredo, Ruth Riisnaes, Susana Miranda, Mateus Crespo, Penny Flohr, Joaquín Mateo, Amelia Altavilla, Roberta Ferraldeschi, Diletta Bianchini, Gerhardt Attard, Nina Tunariu, Johann de Bono
BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB. MATERIALS AND METHODS: A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set...
May 5, 2016: Clinical Genitourinary Cancer
Jesse Ory, Ryan Flannigan, Colin Lundeen, James G Huang, Peter Pommerville, S Larry Goldenberg
PURPOSE: Testosterone deficiency and prostate cancer have an increasing prevalence with age. However, because of the relationship between prostate cancer and androgen receptor activation, testosterone therapy among patients with known prostate cancer has been approached with caution. MATERIALS AND METHODS: We identified a cohort of 82 hypogonadal men with prostate cancer who were treated with testosterone therapy. They included 50 men treated with radiation therapy, 22 treated with radical prostatectomy, 8 on active surveillance, 1 treated with cryotherapy and 1 who underwent high intensity focused ultrasound...
October 2016: Journal of Urology
Andreza Vargas, Roberto Dias Machado, Daniel Ianni Filho, Carlos Eduardo Paiva, Rodolfo Borges Dos Reis, Marcos Tobias-Machado, Eliney Ferreira Faria
PURPOSE: The morbidity associated with metabolic syndrome induced by androgen deprivation therapy (ADT) in prostate cancer (PCa) has not been widely studied. There are no studies comparing surgical and pharmacological castration with regards to their metabolic side effects. The aim of this study was to compare both modalities. METHODS: A prospective observational study was conducted in men with PCa and with indications of any ADT. The participants were divided into two groups: (1) bilateral orchiectomy and (2) LHRH analogs...
April 21, 2016: World Journal of Urology
Per Kongsted, Inge Marie Svane, Henriette Lindberg, Lisa Sengeløv
BACKGROUND: In the present study, we examined possible predictors of chemotherapy-induced toxicity, treatment outcomes, and the consequences of dose reductions in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving standard docetaxel. PATIENTS AND METHODS: Medical records from 421 consecutive patients treated with first-line docetaxel (75 mg/m(2) every 3 weeks) and low-dose prednisolone from 2007 to 2013 at Herlev University Hospital were reviewed...
March 24, 2016: Clinical Genitourinary Cancer
Giuseppe Di Lorenzo, Martina Pagliuca, Teresa Perillo, Alfonso Benincasa, Davide Bosso, Sabino De Placido, Carlo Buonerba
Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient's performance status had improved to 1, the hemoglobin level was 12...
April 2016: Medicine (Baltimore)
Oliver Sartor, Peter Hoskin, Robert E Coleman, Sten Nilsson, Nicholas J Vogelzang, Oana Petrenciuc, Karin Staudacher, Marcus Thuresson, Christopher Parker
BACKGROUND: Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium-223 treatment is of clinical importance. An exploratory analysis of prospectively collected data, from the ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) patient subgroup who received chemotherapy after radium-223 or placebo treatment, was conducted to evaluate the safety and efficacy of chemotherapy following radium-223...
July 2016: Prostate
Larissa K Laskowski, David S Goldfarb, Mary Ann Howland, Kelly Kavcsak, Danny M Lugassy, Silas W Smith
The human monoclonal antibody denosumab inhibits osteoclast-mediated bone resorption by binding to receptor activator of nuclear factor κB ligand (RANKL), which is upregulated by tumor cells. Denosumab is indicated to prevent skeletal-related events (SREs) from osteoporosis and metastatic bone disease. We report a case of denosumab-induced hypocalcemia to highlight potential toxicity and treatment considerations. A 66-year-old man with prostate cancer, small cell lung cancer, and bone metastases presented with fatigue, weakness, and muscle spasm...
September 2016: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
Aseem Anand, Michael J Morris, Steven M Larson, David Minarik, Andreas Josefsson, John T Helgstrand, Peter S Oturai, Lars Edenbrandt, Martin Andreas Røder, Anders Bjartell
BACKGROUND: Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide. METHODS: Retrospectively, we included patients who received enzalutamide as a clinically approved therapy for mCRPC and had undergone bone scan prior to starting therapy...
December 2016: EJNMMI Research
Giannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, Eleni Timotheadou, Fotini Matsiakou, Christos Christodoulou, Konstantinos Laschos, Eleni Galani, Angelos Koutras, Dimitrios Bafaloukos, Helena Linardou, Dimitrios Pectasides, Ioannis Varthalitis, Pavlos Papakostas, Haralambos P Kalofonos, George Fountzilas
Prophylactic erythropoiesis-stimulating agent (ESA) administration for chemotherapy-induced anemia (CIA) is not supported by current guidelines. Long-term follow-up of patients WHO had been treated with ESA for CIA in the past may provide useful information. In 2002, we undertook a prospective, randomized phase III trial of prophylactic vs. hemoglobin (Hb)-based (threshold: 11 mg/dl) ESA administration in patients with solid tumors and CIA. ESA administration FOR CIA was permanently suspended in 2007 in view of published data at that time, while patient surveillance continued...
February 2016: Molecular and Clinical Oncology
Koichi Uemura, Yasuhide Miyoshi, Takashi Kawahara, Shuko Yoneyama, Yusuke Hattori, Jun-ichi Teranishi, Keiichi Kondo, Masatoshi Moriyama, Shigeo Takebayashi, Yumiko Yokomizo, Masahiro Yao, Hiroji Uemura, Kazumi Noguchi
BACKGROUND: The bone scan index (BSI), which is obtained using a computer-aided bone scan evaluation system, is anticipated to become an objective and quantitative clinical tool for evaluating bone metastases in prostate cancer. Here, we assessed the usefulness of the BSI as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated using docetaxel. METHODS: We analyzed 41 patients who received docetaxel for mCRPC. The Bonenavi system was used as the calculation program for the BSI...
2016: BMC Cancer
Eberhard Varenhorst, Rami Klaff, Anders Berglund, Per Olov Hedlund, Gabriel Sandblom
Approximately 15% of men with hormone naïve metastatic prostate cancer primarily fail to respond to androgen deprivation treatment (ADT). The reason why the response to ADT differs in this subgroup of men with prostate cancer remains unclear. The aim of this study was to describe the characteristics of these men and to thereby define predictors of early ADT failure in prostate cancer patients with bone metastases. The study was based on 915 men from the prospective randomized multicenter trial (no. 5) conducted by the Scandinavian Prostate Cancer Group comparing parenteral estrogen with total androgen blockade...
March 2016: Cancer Medicine
Li Feng, Mei-Kuang Chen, Nada Lukkahatai, Chao-Pin Hsiao, Aradhana Kaushal, Lee Sechrest, Leorey N Saligan
BACKGROUND: Fatigue is one of the most distressing symptoms experienced by people with cancer receiving radiation therapy. OBJECTIVES: The goal of this study is to evaluate clinical predictors of worsening fatigue during external beam radiation therapy (EBRT) in men with non-metastatic prostate cancer. METHODS: Thirty-five men with non-metastatic prostate cancer scheduled for EBRT were followed at baseline, midpoint, and completion of EBRT...
December 2015: Clinical Journal of Oncology Nursing
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"